Grade 2 and above AEs at least possibly related to neratinib (N = 16)
| AE . | Grade 2, N (%) . | Grade 3, N (%) . | Total, N (%) . |
|---|---|---|---|
| Diarrhea | 7 (44%) | 4 (25%)* | 11 (69%) |
| Anorexia | 7 (44%) | 0 | 7 (44%) |
| Fatigue | 4 (25%) | 1 (6%) | 5 (31%) |
| Anemia | 3 (19%) | 0 | 3 (19%) |
| Nausea | 3 (19%) | 0 | 3 (19%) |
| Dehydration | 1 (6%) | 1 (6%) | 2 (13%) |
| Dyspepsia | 2 (13%) | 0 | 2 (13%) |
| Hypophosphatemia | 2 (13%) | 0 | 2 (13%) |
| Vomiting | 2 (13%) | 0 | 2 (13%) |
| Syncope | 0 | 1 (6%) | 1 (6%) |
| AE . | Grade 2, N (%) . | Grade 3, N (%) . | Total, N (%) . |
|---|---|---|---|
| Diarrhea | 7 (44%) | 4 (25%)* | 11 (69%) |
| Anorexia | 7 (44%) | 0 | 7 (44%) |
| Fatigue | 4 (25%) | 1 (6%) | 5 (31%) |
| Anemia | 3 (19%) | 0 | 3 (19%) |
| Nausea | 3 (19%) | 0 | 3 (19%) |
| Dehydration | 1 (6%) | 1 (6%) | 2 (13%) |
| Dyspepsia | 2 (13%) | 0 | 2 (13%) |
| Hypophosphatemia | 2 (13%) | 0 | 2 (13%) |
| Vomiting | 2 (13%) | 0 | 2 (13%) |
| Syncope | 0 | 1 (6%) | 1 (6%) |
NOTE: AEs that are grade 2 or above experienced by more than one patient or any occurrence of grade 3 AEs are included.